Oral Immunization of Wildlife Against Rabies: Concept and First Field Experiments

The possibility of immunizing carnivores against rabies with live attenuated vaccine administered by the oral route was raised by North American scientists in the 1960s. Subsequently, several American and European teams tested different vaccine strains in the laboratory for efficacy and safety and studied vaccine stabilization, vaccine delivery systems, baIt acceptance by wl1d ammals, and bait distribution schemes. The first field trial of a cloned SAD (Street Alabama Dufferin) strain in baits designed to immunize foxes orally ~as conducted in an Alpine valley in Switzerland in 1978. A population containing ∼60% immune foxes at the valley entrance stopped the spread of the disease into untreated upper parts of the valley. T~e strategic use of oral vaccination of foxes in additional regions of SWItzerland resulted m freedom from the zoonosis in four-fifths of the countr

Dog Ecology and Dog Rabies Control

Dog populations, like other populations, depend on the availability of resources (food, water, and shelter). Humans either make available or deliberately withhold resources for varying proportions of dog populations. Dog-keeping practices and the duties of responsible ownership vary with the cultural setting. Dog populations often attain densities that allow the species to be a main host of rabies. The epidemiology of dog rabies is not well understood, despite the easy access to dog populations. Today dog rabies is predomina~t in developing countries. In addition to the high rate of exposure of humans to dogs, tradItional medical beliefs and practices are the most important cultural factors that lead to high numbers of cases of human rabies. Dog rabies control programs have been succe~sful in the past, but most are failing today. Program development should follow managenal principles and take into consideration the biology of dog populations as w~ll as. cultural constraints. Elimination of stray dogs IS not an effIcIent means of controllIng eIther the dog population or rabies, but it may create public awarenes

Oral Immunization of Wildlife Against Rabies: Concept and First Field Experiments

The possibility of immunizing carnivores against rabies with live attenuated vaccine administered by the oral route was raised by North American scientists in the 1960s. Subsequently, several American and European teams tested different vaccine strains in the laboratory for efficacy and safety and studied vaccine stabilization, vaccine delivery systems, baIt acceptance by wl1d ammals, and bait distribution schemes. The first field trial of a cloned SAD (Street Alabama Dufferin) strain in baits designed to immunize foxes orally ~as conducted in an Alpine valley in Switzerland in 1978. A population containing ∼60% immune foxes at the valley entrance stopped the spread of the disease into untreated upper parts of the valley. T~e strategic use of oral vaccination of foxes in additional regions of SWItzerland resulted m freedom from the zoonosis in four-fifths of the country

Paper Session I-A - Titan IV Integrate. Test and Launch Facility System Improvements

In order to sustain our quest for new frontiers, we must first appreciate how we attained our present accomplishments. We are transitioning from the research and development phase into the operational phase of accessing space. Three decades ago we struggled with the idea of placing a basketball sized satellite into space and today the Titan IV system is installing school bus size payloads in Earth orbit and beyond. The scope of this paper is to briefly describe the Titan IV system, including the flight hardware, facilities and ground equipment, and explain how this system is improving at the Eastern Launch Site (ELS) to assure reliable, cost effective access to space for the Department of Defense (DoD) larger payloads

Epidermolysa bullosa in Danish Hereford calves is caused by a deletion in LAMC2 gene

BACKGROUND Heritable forms of epidermolysis bullosa (EB) constitute a heterogeneous group of skin disorders of genetic aetiology that are characterised by skin and mucous membrane blistering and ulceration in response to even minor trauma. Here we report the occurrence of EB in three Danish Hereford cattle from one herd. RESULTS Two of the animals were necropsied and showed oral mucosal blistering, skin ulcerations and partly loss of horn on the claws. Lesions were histologically characterized by subepidermal blisters and ulcers. Analysis of the family tree indicated that inbreeding and the transmission of a single recessive mutation from a common ancestor could be causative. We performed whole genome sequencing of one affected calf and searched all coding DNA variants. Thereby, we detected a homozygous 2.4 kb deletion encompassing the first exon of the LAMC2 gene, encoding for laminin gamma 2 protein. This loss of function mutation completely removes the start codon of this gene and is therefore predicted to be completely disruptive. The deletion co-segregates with the EB phenotype in the family and absent in normal cattle of various breeds. Verifying the homozygous private variants present in candidate genes allowed us to quickly identify the causative mutation and contribute to the final diagnosis of junctional EB in Hereford cattle. CONCLUSIONS Our investigation confirms the known role of laminin gamma 2 in EB aetiology and shows the importance of whole genome sequencing in the analysis of rare diseases in livestock

Approaches to assess IgE mediated allergy risks (sensitization and cross-reactivity) from new or modified dietary proteins

The development and introduction of new dietary protein sources has the potential to improve food supply sustainability. Understanding the potential allergenicity of these new or modified proteins is crucial to ensure protection of public health. Exposure to new proteins may result in de novo sensitization, with or without clinical allergy, or clinical reactions through cross-reactivity. In this paper we review the potential of current methodologies (in silico, in vitro degradation, in vitro IgE binding, animal models and clinical studies) to address these outcomes for risk assessment purposes for new proteins, and especially to identify and characterise the risk of sensitization for IgE mediated allergy from oral exposure. Existing tools and tests are capable of assessing potential crossreactivity. However, there are few possibilities to assess the hazard due to de novo sensitization. The only methods available are in vivo models, but many limitations exist to use them for assessing risk. We conclude that there is a need to understand which criteria adequately define allergenicity for risk assessment purposes, and from these criteria develop a more suitable battery of tests to distinguish between proteins of high and low allergenicity, which can then be applied to assess new proteins with unknown risks. © 2017 The Authors Chemicals/CAS: immunoglobulin E, 37341-29-